INTRODUCTION
The gene for SRC-3 (also known as AIB1, ACTR, p/CIP, TRAM-1, and RAC3) was reported to be amplified in $5%-10% of human breast tumors and overexpressed in $60% of tumors, suggesting that SRC-3 provides a growth advantage for breast cancer cells (Anzick et al., 1997) . SRC-3 is a bona fide oncogene and plays a role in initiation and progression of mammary gland tumorigenesis (Kuang et al., 2004; Torres-Arzayus et al., 2004) . The transcriptional coactivation activity of SRC-3 is subject to regulation by posttranslational modifications such as phosphorylation (Font de Mora and Brown, 2000; Wu et al., 2002 Wu et al., , 2004 . Phosphorylation of SRC-3 was recently demonstrated to be important for coactivation of select steroid receptors and was linked to its proliferative/oncogenic potential . Although the mechanisms underpinning normal regulation of cellular SRC-3 levels are not completely known, the process appears to be complex and to involve both ubiquitin-dependent and -independent proteasome pathways (Li et al., 2006; Lonard et al., 2004) .
Ubiquitination plays a major role in the regulation of cellular processes, and the best-studied function of ubiquitination is its role in protein degradation (Varshavsky, 2005) . Among the E3 ubiquitin ligases, the SCF complexes are a well-studied class of E3s; the F box protein subunit of SCF directly binds to substrates and often confers substrate specificity (Elledge and Harper, 1998) . Of the identified F box proteins, Skp2 and Fbw7 (hCdc4, Sel10, hAgo) are known to control the levels of several key regulatory proteins in the cell cycle (Bornstein et al., 2003; Kamura et al., 2003; Moberg et al., 2001) .
Although cellular signaling and SRC-3 protein turnover both affect the physiological functions and activity of SRC-3, it was unclear as to whether signaling regulates the cellular levels/turnover of SRC-3 and how, in turn, it may impact SRC-3 transcriptional function. In the current report, we show that cellular signaling regulates both transcriptional activation and turnover of SRC-3 through a coupled phosphorylation-dependent ubiquitination code. We demonstrate that phosphorylation of a critical peptide element (actron/degron) surrounding S505 is required for the subsequent ubiquitination of SRC-3 and we further identify GSK3 and SCF Fbw7a as the responsible kinase and E3 ligase, respectively. Our results advance our understanding of SRC-3 degradation but, importantly, uncover a nonproteolytic ''activation'' function for SRC-3 ubiquitination. We found that phosphorylation-dependent multi-(mono)ubiquitination promotes SRC-3 transcription factor specificity and coactivator function. We propose that select cellular signals regulate SRC-3 transcriptional activation and turnover by the means of a ''phosphorylation-dependent ubiquitination code.'' In this manner, transcription-and phospho-dependent ubiquitination of SRC-3 acts as a ''time clock'' for its functional lifetime.
RESULTS

SRC-3 Is a Genuine Substrate of the Akt/PKB-GSK3 Signaling Pathway
Since the Akt/PKB signaling pathway is activated in many types of cancers (Brazil et al., 2004) and SRC-3/AIB1 has been shown to be a bona fide oncogene, we investigated the existence of crosstalk between Akt/PKB and SRC-3 signaling. We stably expressed a constitutively active form of Akt/PKB (CA-Akt) in MCF-7 breast cancer cells and determined the effects of Akt/PKB activation on the phosphorylation of SRC-3. Expression of the constitutive Akt/PKB was detected by western blotting with anti-HA, and expression of the constitutive Akt/PKB resulted in increased phosphorylation of its downstream target, glycogen synthase kinase-3 (GSK3), as revealed by western blotting using phospho-specific antibodies against GSK3 ( Figure 1A ). Since the phosphorylation status of SRC-3 was shown to be important for its function, we determined the effects of CA-Akt/PKB expression on the phosphorylation of SRC-3 . Among six known phosphorylation sites (pT24, pS505, pS543, pS857, pS860, and pS867), phosphorylation on S505 was found to be significantly reduced ($70%) upon expression of CA-Akt. Given that expression of CA-Akt reduced phosphorylation of S505 ( Figure 1B) , it suggested that S505 may be phosphorylated by a kinase whose activity is inhibited by Akt/ PKB. To identify this Akt/PKB-regulated kinase, we focused on GSK3 for the following reasons. The activity of GSK3 is known to be inhibited by Akt/PKB through phosphorylation on critical residues (Cohen, 1999) , and expression of CA-Akt resulted in increased phosphorylation of GSK3 in MCF-7 ( Figure 1A ). GSK3 is one of the kinases that we previously showed to phosphorylate SRC-3 on S505 in vitro , and sequence analysis revealed S505 to be a perfect GSK3 consensus phosphorylation site ( Figure 1C ).
For GSK3 to phosphorylate a substrate protein, it often requires a priming phosphorylation, i.e., prior phosphorylation of an amino acid sequence of four amino acids C-terminal (+4) to the GSK3 target site (0) ( Figure 1C ). We noted that, in addition to S509, three additional potential priming sites for GSK are present (T513, S517, and (A) An Akt/PB expression construct that contains the myristoylation signal was transfected into the MCF-7 cells to stably express this constitutively active Akt/PKB (CA-Akt). The expression of the CA-Akt was confirmed by western blotting, and the consequence of CA-Akt expression was verified by the increased phosphorylation of its direct target, GSK3, with antipS21/S9 of GSK3a/b. n.s., nonspecific. (B) The effects of CA-Akt expression on the phosphorylation status of SRC-3 were determined by the western blotting with each of the phospho-specific antibodies as previously described . The numbers reflected the ratio of the values of phosphorylated SRC-3/total SRC-3 between the CA-Akt-expressing cells and the control cells (pCR3.1), which was set at 1 for each panel. Shown is a representative western blotting result from two independent experiments with similar results. (C) Sequence analysis revealed a perfect GSK3 consensus phosphorylation site in SRC-3. Arrows indicated possible priming phosphorylation sites. (D) The phosphorylation of S505 on the indicated SRC-3 was determined by western blotting with anti-phospho-S505 as described in (A). The priming phosphorylation site for phosphorylation of S505 by GSK3 was determined to be S509. (E) A summary of the proposed signaling events, comprised of Akt/PKB and GSK3 that regulate S505 phosphorylation on SRC-3. All Quantification was performed by the NIH Image program. S521) that could initiate this phosphorylation event. We mutated each of these potential phosphorylatable amino acids to alanines and determined which mutation interrupted the phosphorylation of S505. Our results showed that phosphorylation of S505 was not affected by mutations of T513, S517, or S521 (Figure 1Di ). In contrast, phosphorylation of S505 was abolished when S509 was mutated to alanine ( Figure 1Dii ). As controls for the phospho-specific antibody, mutation of S505 to alanine (S505A) or glutamic acid (S505E) prevented the detection of SRC-3 by the antibody. Thus, phosphorylation of S505 requires a priming phosphorylation at S509, and we identified SRC-3 to be a likely GSK3 substrate.
Phosphorylation of S505 Regulates SRC-3 Protein Turnover As shown in Figure 1B , we consistently observed an increased level of SRC-3 when cells expressed CA-Akt, suggesting that inhibition of S505 phosphorylation increases the stability of SRC-3. We first used a pharmacological agent, LiCl, to inhibit GSK3 activity (Klein and Melton, 1996) . Consistent with an earlier report (Lonard et al., 2004) , the half-life of endogenous SRC-3 in MCF-7 cells that did not receive LiCl treatment was determined to be $3-4 hr (Figures 2A and 2B ). In contrast, LiCl treatment dramatically stabilized SRC-3 in MCF-7 cells, and no significant reduction of SRC-3 protein was evident in the presence of cycloheximide after 10 hr (Figures 2A and 2B) . Accordingly, phosphorylation of S505 sampled at the 10 hr point was found to be abolished in cells treated with LiCl ( Figure 2B , inset), suggesting that phosphorylation of S505 by GSK3 correlates with SRC-3 stability.
We compared the half-life of wild-type SRC-3 with SRC-3 carrying S505 mutated to alanine (S505A). Wildtype SRC-3 transiently expressed in HEK293 cells exhibits a half-life ($4 hr) similar to its endogenous counterpart from MCF-7 cells, while the SRC-3 (S505A) mutant displayed a much longer half-life ( Figure 2D) . A control SRC-3 mutant (T24A) showed a similar half-life to the wild-type SRC-3.
GSK3 Regulates Phosphorylation and Functional Levels of SRC-3
Knockdown of GSK3a (Figure 3Ai ) or GSK3b (Figure 3Aii ) by siRNA in MCF-7 cells resulted in elevated cellular SRC-3 levels as compared to control. Increased SRC-3 protein is a result of increased half-life as evidenced by the knockdown of GSK3 (Figure 3Aiii ). In addition, expression of either GSK3a or GSK3b enhanced SRC-3 phosphorylation at S505 ( Figure 3B ). These results are in line with data from Figure 2 and indicate that GSK3 promotes SRC-3 turnover in an S505 phosphorylation-dependent fashion. Sequence comparison revealed that SRC-3 contains a degradation motif similar to that found in several other important cellular growth-regulatory proteins (Figure 3C) (Doble and Woodgett, 2003; Oberg et al., 2001; Wei et al., 2005; Welcker et al., 2004) . (A) The effects of LiCl, a specific inhibitor of GSK3 kinase activity, on the half-life of endogenous SRC-3 from MCF-7 cells were determined. MCF-7 cells pretreated or not with LiCl (10 mM) for 2 hr were subsequently treated with cycloheximide (20 mg/ml), and samples were collected at the indicated times after addition of cycloheximide to determine the SRC-3 levels. Shown is a representative western blotting results from two independent cycloheximide chase experiments with similar results. The inset shows that S505 phosphorylation is reduced from samples collected from a parallel experiment that were treated or not with LiCl for 10 hr. We next demonstrated that GSK3b augmented SRC-3 ubiquitination (Figure 3Di ). The kinase activity of GSK3b was required since kinase-defective GSK3b did not enhance SRC-3 ubiquitination (Figure 3Dii ). Stimulation of resting cells with physiological stimuli, such as EGF and insulin, resulted in inhibition of GSK3 activity and elevated (A) MCF-7 cells were transfected with siRNAs specific for either GSK3a (Ai), GSK3b (Aii), or GSK3a and GSK3b combined (Aiii). The effects of knockdown of GSK3 on the levels and half-life of SRC-3 were determined by western blotting with anti-SRC-3. The b-actin served as a protein loading control. (B) Flag-SRC-3 was cotransfected with either GSK3a or GSK3b into HEK293 cells to determine the effects of GSK3 expression on phosphorylation of S505. Phosphorylation of S505 was determined by western blotting with anti-phospho-S505. The immunoprecipitated Flag-SRC-3 and the expression of GSK3a and GSK3b were shown. (C) Sequence alignment of several phosphodegron-containing proteins. (Di) All the following experiments to examine the ubiquitination of SRC-3 in cells were performed essentially as described in Experimental Procedures. Briefly, protein extracts from HEK293 cells cotransfected with Flag-SRC-3, HA-ubiquitin, and with or without Myc-GSK3b were immunoprecipitated with anti-Flag. The possible ubiquitination of Flag-SRC-3 from the immunoprecipitates was examined by western blotting with anti-Flag. (Dii) As in (Di) except a kinase-defective GSK3b was used. (E) Protein extracts and total RNA from MCF-7 cells treated with EGF (100 ng/ml) or insulin (1 mM) alone or in combination with the indicated kinase inhibitors (25 mM each) were analyzed by the indicated antibodies or RT-PCR. levels of SRC-3 ( Figure 3E , fourth and first panels, lanes 1-3). The elevated levels of SRC-3 were associated with decreased S505 phosphoryation and SRC-3 ubiquitination ( Figure 3E, second and third panels, lanes 1-3) . The effects of EGF and insulin were not at the transcriptional levels, as SRC-3 mRNA was not affected and pretreatment with proper kinase inhibitors abolished the effects. Our results indicate that phosphorylation of S505 by GSK3 targets SRC-3 for degradation by a phosphorylation-dependent ubiquitin-proteasome pathway.
SCF
Fbw7a Is an SRC-3-Specific E3 Ligase that Regulates SRC-3 Ubiquitination and Nuclear Turnover in a Phosphorylation-Dependent Manner To demonstrate that S505 phosphorylation is directly involved in SRC-3 ubiquitination, we examined the extent of ubiquitination observed for SRC-3 phosphorylation mutants. Our results showed that mutation of S505 to alanine (S505A) decreased the extent of SRC-3 ubiquitination, and substitution of glutamic acid at S505 (S505E) significantly increased SRC-3 ubiquitination when compared to the wild-type SRC-3 ( Figure 4A , top panel, compare lanes 2-4).
Since ubiquitin E3 ligases are most responsible for determining substrate specificity (Hershko and Ciechanover, 1998; Varshavsky, 1997) and the sequences surrounding S505 are similar to those proteins whose abundance is regulated by Fbw7 (hCdc4, sel10, hAgo) ( Figure 3C ) (Koepp et al., 2001; Moberg et al., 2001; Oberg et al., 2001) , we examined whether Fbw7 plays a role in the ubiquitination of SRC-3. Among the three isoforms of Fbw7 (Fbw7a, Fbw7b, and Fbw7g), only Fbw7a coimmunoprecipitated with wild-type SRC-3 (data not shown; Figure 4A , third panel from top, lane 2); the amount of Fbw7a coimmunoprecipitated with S505A was less than that obtained from wild-type SRC-3 ( Figure 4A , third panel from top, lane 3). In contrast, the amount of Fbw7a found associated with S505E was substantially more than that of wild-type SRC-3 ( Figure 4A , third panel from top, lane 4), and Fbw1a and Fbw1b (b-TrCP) were not detected ( Figure 4A , fourth panel from top and data not shown). Our results suggested that Fbw7a is an E3 ligase that might specifically control SRC-3 cellular turnover through phosphorylation-dependent ubiquitination. In support, our data further revealed that siRNA knockdown of Fbw7 (particularly Fbw7a) resulted in elevated levels of SRC-3 ($50%) in MCF-7 cells (Figure 4Bi ). Conversely, overexpression of Fbw7a markedly decreased the halflife of SRC-3 ( Figure 4Bii ). Figure 4Ci shows that phosphorylation of S505 by GSK3 (middle panel, lanes 1 and 2) enhanced the binding of Fbw7a to SRC-3 (top panel, lanes 1 and 2); mutation of S505 to alanine (S505A) prevented phosphorylation by GSK3 (middle panel, lanes 3 and 4) and abolished the enhancement in binding (top panel, lanes 3 and 4). We next showed that expression of Fbw7a efficiently decreased the levels of the wild-type SRC-3 in a dosage-dependent manner ( Figure 4Cii, lanes 1-3) . The effect of Fbw7a on SRC-3 levels at a lower dosage (SRC-3: Fbw7a = 1:5) was attenuated when S505 was mutated to alanine (S505A) (compare lanes 2 and 5), but not at a higher dosage (SRC-3: Fbw7a = 1:25, lanes 3 and 6). The effect of Fbw7a on SRC-3 levels was completely abolished even at a higher dosage of Fbw7a (SRC-3: Fbw7a = 1:25) when the priming phosphorylation site S509 was mutated to alanine (S509A) (lanes 7-9). As expected, no effects were observed when both S505 and S509 were mutated to alanines (S505/509A) (lanes 10-12). Taken together, our results identify a critical degron signaling element in SRC-3 and demonstrate that phosphorylations of both S505 and S509 within this element are important for Fbw7a to regulate SRC-3 turnover. We next investigated whether this event is mediated by phosphorylation-dependent ubiquitination. Because Fbw7a promoted SRC-3 degradation, and to aid in the detection of ubiquitinated SRC-3, we changed the ratio of SRC-3 versus Fbw7a to 1:1 (as compared to 1:5 and 1:25 in Figure 4Cii ). Our results showed that Fbw7a clearly enhanced ubiquitination of the wild-type SRC-3 ( Figure 4D , lanes 1 and 2) and that this enhancement was attenuated or completely abolished when either S505 (S505A) (lanes 3 and 4) or the priming phosphorylation site S509 (S509A) was mutated to alanine (lanes 5 and 6), respectively.
Interestingly, the molecular weights of the ubiquitinated species suggested that SRC-3 was largely multi-(mono)-ubiquitinated and not polyubiquitinated under our test conditions (Figures 4D and 5G and Figure S1 in the Supplemental Data available with this article online). Since it is accepted that ubiquitin/proteasome degradation requires the formation of a ubiquitin chain of at least four ubiquitins (polyubiquitination) on the same lysine of target proteins, we tested whether Fbw7a also promotes eventual polyubiquitination of SRC-3. Indeed, despite the fact that multi-(mono)ubiquitination comprises the majority form of SRC-3, both multi-(mono)ubiquitination and polyubiquitination of SRC-3 could be enhanced by Fbw7a in a dosage-dependent manner ( Figure 4E , lanes 1-3; note the ratios of SRC-3 and Fbw7a [1:2 and 1:5] were within the lower range [1:5] used in Figure 4C to aid in the detection of ubiquitinated SRC-3). As a control, the ability of Fbw7a to enhance SRC-3 ubiquitination required the F box of Fbw7a, a region responsible for the recruitment of the SCF complex; an F box deletion mutant (delF) was incapable of enhancing SRC-3 ubiquitination ( Figure 4F ).
We tested the effects of Fbw7a on the ubiquitination of SRC-1 and SRC-2 family members. Despite being ubiquitinated, the ubiquitination of SRC-1 and SRC-2 was not enhanced by Fbw7a ( Figure 4G , lanes 1-4, long and short exposure), demonstrating an unexpected degree of specific ubiquitination enhancement by Fbw7a on SRC-3. Since the critical regulatory element spanning S505-S509 in SRC-3 was not present in the corresponding regions of SRC-1 or SRC-2, we exchanged the corresponding sequences in SRC-2 ( Ubiquitination of Flag-SRC-3 from the immunoprecipitates was examined by anti-HA. Afterward, the membrane was stripped and reprobed with the following antibodies: anti-SRC-3, anti-Fbw7, and anti-Fbw1a and 1b (this antibody detected Fbw1 from total cell lysate, data not shown). n.s., nonspecific; IgH, immunoglobulin heavy chain. The position of unmodified SRC-3 after alignment of the top two panels was indicated.
(Bi) SRC-3 protein levels from the Fbw7 knockdown cells were determined by anti-SRC-3. The b-actin was used as a protein loading control. The values below represented the relative intensity of Fbw7 and SRC-3 from control and specific siRNA-transfected cells. (Bii) To determine the effects of Fbw7a on the half-life of SRC-3, Flag-SRC-3 was cotransfected with myc-Fbw7a into HEK293 cells and treated with cycloheximide (20 mg/ml) for the indicated times.
(Ci) Wild-type SRC-3 (GST-S/T S505) and mutant (GST-S/T S505A) were phosphorylated by GSK3 in vitro where indicated and used in a GST pull-down assay by incubating with radioactive Fbw7a. (Cii) The indicated Flag-SRC-3 (0.2 mg) was cotransfected with different amounts of Flag-Fbw7a (1 mg andsame ubiquitination characteristics as native SRC-3. SRC-2/ 515 SPMAS 519 also showed increased phosphorylation of S515 (equivalent of S505 in SRC-3) to a similar extent as SRC-3 (Figure 4Hii, top panel, lanes 1-3) . Importantly, ubiquitination of SRC-2/ 515 SPMAS 519 and not wild-type SRC-2 was susceptible to enhancement by Fbw7a ( Figure 4I , lanes 2 and 4). Taken together, our results identify an SRC-3-specific degron element (   505   SPMAS   509 ) that is targeted by SCF Fbw7a for ubiquitination in a phosphorylation-dependent manner.
Potential SRC-3 Ubiquitination Sites and SRC-3 Multi-(Mono)Ubiquitination
We next divided full-length SRC-3 into five regions ( Figure 5A ) to determine where ubiquitination occurred. We focused our attention on the RID and HAT regions, as they contain functionally characterized motifs and were more efficiently ubiquitinated ( Figure 5B ). We found two and then one perfect sumoylation/ubiquitination consensus sequences (fKXE: f, hydrophobic; K, lysine; X, any amino acid; E, glutamic acid) within the RID and HAT regions, respectively ( Figure 5C ) (Desterro et al., 1998; Hoege et al., 2002) . We mutated the lysine residue in each of these three sites to arginine and noted that individual mutations of K723 or K786 to arginines significantly reduced ubiquitination as compared to the wild-type SRC-3 ( Figure 5D , lanes 1-3); mutation of K1194 to arginine did not affect SRC-3 ubiquitination ( Figure 5D , lane 4). To test whether Fbw7a could directly ubiquitinate SRC-3, an in vitro ubiquitination assay was performed. Mutation of the two potential ubiquitination sites (K723 and K786) to arginines significantly reduced SRC-3 ubiquitination by Fbw7a (Figure 5Eiii , compare lanes 3 and 4 to 2). Interestingly, mutation of S505 to alanine also reduced ubiquitination of SRC-3 by Fbw7a (lane 5). Our results further substantiate that phosphorylation of S505 is involved in the regulation of SRC-3 ubiquitination and that K723 and K786 represent the prime candidate sites for ubiquitination by Fbw7a.
To examine whether ubiquitination on K723 and K786 is important for SRC-3 stability, we showed that Fbw7a reduced the levels of wild-type SRC-3 in a dosage-dependent manner (Figure 5Fi , lanes 1-3; note that the ratios used were the same as in Figure 4C ). In contrast, the K723R and K786R mutants demonstrated resistance to degradation at both low and high concentrations of Fbw7a (lanes 2, 3, 5, 6, 8, and 9). In support, our results showed that the half-lives of K723R and K786R mutants were substantially longer than the wild-type SRC-3 (Figure 5Fii ).
We remained surprised that the majority of ubiquitinated SRC-3 appeared to be predominantly multi-(mono)-ubiquitinated and not polyubiquitinated in form ( Figure S1 ; Figures 4D and 4E ). To substantiate that SRC-3 is indeed multi-(mono)ubiquitinated, we showed that treatment with the proteasome inhibitor MG132 resulted in an accumulation of extensively polyubiquitinated SRC-3 that was barely detectable in the absence of MG132 (Figure 5Gi , lanes 1 and 2). The strikingly different SRC-3 ubiquitination pattern in the presence of MG132 suggested that the phosphoactivated SRC-3 is mainly multi-(mono)ubiquitinated and that the polyubiquitinated forms are more unstable and transient.
To unequivocally demonstrate that SRC-3 is multi-(mono)ubiquitinated, we compared ubiquitination patterns in the presence of wild-type ubiquitin or a ubiquitin mutant molecule with all seven lysines mutated to arginines (UbKO). Because this ubiquitin mutant (UbKO) lacks all potential sites for polyubiquitination, the UbKO molecule supports only multi-(mono)ubiquitination on SRC-3. Importantly, the SRC-3 ubiquitination patterns formed in the presence of the wild-type ubiquitin were found to be representative of that formed with UbKO ( Figure 5Gii , lanes 1 and 2). This conclusion is further supported by triple antibody (anti-Flag, anti-HA, anti-SRC-3) purification experiments (see Supplemental Experimental Procedures and Figure S1 for details) where similar ubiquitination patterns as that in (ii) were obtained (Figure 5Giii ). In brief, two tags were placed on different proteins, i.e., Flag tag on SRC-3 and HA tag on ubiquitin, and the final purified products were detected by a third specific antibody to SRC-3. Because the captured proteins after the first round of purification were released by heating at 95 C, we conclude that the detected bands are indeed modified by HA tag containing Ub (HA-Ub-Flag-SRC-3) and are not simply SRC-3-associated proteins. Taken together, our results substantiate that although both multi-(mono)ubiquitination and polyubiquitination occur on SRC-3 ( Figure 4E ), the predominant phosphorylation-dependent form of SRC-3 is mainly multi-(mono)ubiquitinated.
Phosphorylation-Dependent Nonproteolytic Activational Functions of SRC-3 Ubiquitination
The ubiquitin/proteasome pathway has been implicated in transcriptional functions of nuclear receptors and their coactivators, but the underlying mechanisms are not defined (Lonard et al., 2004) . Since phosphorylation of SRC-3 at S505 and S509 regulated the ubiquitination of SRC-3, we addressed the functional importance of these two potential ubiquitination sites, K723 and K786, for the transcriptional activation capacity of SRC-3. Since K723 and K786 reside in close proximity to the receptor interaction motifs (LXXLL) of SRC-3 ( Figure 6A ), we first employed coimmunoprecipitation to determine whether ubiquitination affects the ability of SRC-3 to interact with its preferred NR, ER, using SRC-3 mutants carrying individual mutations to arginine at K723 (K723R), K786 (K786R), or K1194 (K1194R). As expected, the binding between ER and wild-type SRC-3 was strongly induced by the addition of the cognate ligand, estradiol ( Figure 6B , top panel, lanes 1 and 2). The ligand-induced interactions between ER and the K723R or K786R SRC-3 mutants were markedly reduced ( Figure 6B , top panel, lanes 3-6), whereas a control mutation at K1194 (K1194R) did not affect the cellular interaction with ER ( Figure 6B , top panel, lanes 7 and 8). Despite the fact that K723R and K786R SRC-3 mutants were defective in interacting with ER, these two mutants interacted with CBP equally well, as did wild-type SRC-3 (Co-IP) ( Figure 6C , top two panels), indicating that the observed defect in protein-protein interaction is selective for ER. Phosphorylation of S118 on ER is a site known to be required for efficient ER transcriptional activity, and the degree of S118 phosphorylation induced by estradiol can represent corroborative in vivo evidence of SRC-3 recruitment and ER activity. We found that cellular phosphorylation of S118 on ER was reduced in the presence of K723R and K786R SRC-3 mutants as compared to that induced by wild-type and K1194R SRC-3 ( Figure 6B , fourth panel from top, lanes 2, 4, 6, and 8). This difference was not due to altered SRC-3 subcellular localization since mutations did not alter the distribution of SRC-3 ( Figure S2 ). Our results indicate that ubiquitination at K723 and K786 are important for SRC-3 to efficiently interact with ER.
We next investigated whether Fbw7a is involved in ER activation of transcription. Our results showed that Fbw7a is a potent co-coactivator of ER activity in the presence of wild-type SRC-3 in a reporter assay (Figure 6Di , columns 4 and 6). The potentiation of ER activity by Fbw7a was decreased when K723 or K786 but not K1194 were individually mutated to arginine (Figure 6Di , columns 6, 8, 10, and 12). Fbw7a also functions as a cocoactivator for AR, and ubiquitinations of K723 and K786 are important for AR activity (Figure 6Dii ). Importantly, the K723R and K786R SRC-3 mutants also showed a reduced activity in a reporter gene assay in the absence of cotransfected Fbw7a ( Figure S3 ) as well as a reduced ability to induce the expression of an endogenous ER target gene (pS2) in response to estradiol as compared to the wild-type SRC-3 and control mutant (K1194R) SRC-3 ( Figure 6E , lanes 2, 4, 6, and 8).
To support the important roles of GSK3 and Fbw7a in ER activation, we examined the effects of GSK3 and Fbw7a knockdown on the induction of several endogenous ER target genes, namely the pS2, c-Myc, and PR, by estradiol. Knockdown of GSK3 or Fbw7 (Figure 6Fi ) significantly reduced the estradiol-iuduced expression of pS2, c-Myc, and PR (ii, iii, and iv, respectively). Since phosphorylation of S505 on SRC-3 is induced by estradiol and phosphorylation of S505 is required for the binding and ubiquitination of SRC-3 by Fbw7a, we investigated the recruitment of Fbw7a to the promoters of pS2 and PR by chromatin immunoprecipitation (ChIP) assays. Our results showed that Fbw7a was specifically recruited to the promoters of pS2 and PR (compare to the control cyclophilin promoter) along with SRC-3 and ER in an estradiol-dependent manner ( Figure 6Gi) ; knockdown of Fbw7 significantly reduced the recruitment of SRC-3 and ER (Figure 6Gii ).
Ubiquitination Enhances the Transcriptional Activity of SRC-3
To further substantiate the importance of SRC-3 ubiquitination in this NR-mediated transcriptional event, we found that SRC-3 ubiquitination was enhanced by estradiol (and a ligand for AR, R1881) (Figure 7Ai, top panel, lanes 1 and 2; (D) The indicated Flag-SRC-3 construct was cotransfected with HA-ubiquitin into HEK293 cells and immunoprecipitated with anti-Flag. Ubiquitination of proteins from the immunoprecipitates was examined by anti-HA (top panel). (Ei) Shown is the 6xHis-Fbw7a purified from sf9 cells. (Eii) Shown is the SRC-3 proteins purified from transfected HEK293 cells. (Eiii) In vitro ubiquitination of SRC-3 by Fbw7a was performed using the purified proteins shown in (Ei) and (Eii) reconstituted with purified E1, UbcH5, and ubiquitin. (Fi) Experiments were performed as in Figure 4C , except K723R and K786R SRC-3 mutants were used. (Fii) HEK293 cells were transfected with the expression constructs for the Flag-tagged wild-type, K723R, or K786R SRC-3. Western blotting with anti-Flag was performed on samples collected after cycloheximide (20 mg/ml) treatment at the indicated time to determine the Flag-SRC-3 levels. The intensity at the beginning of cycloheximide treatment (time 0) is set as 1 for each group. (Gi) Protein extracts from HEK293 cells cotransfected with Flag-SRC-3 and HA-ubiquitin treated or not with proteasome inhibitor MG132 (20 mM) for 6 hr were immunoprecipitated with anti-Flag. Ubiquitination from the immunoprecipitates was examined by anti-HA. (Gii) Protein extracts from HEK293 cells cotransfected with Flag-SRC-3 and wild-type HA-ubiquitin or HA-ubiquitin mutant (UbKO) were immunoprecipitated with anti-Flag and analyzed as in (Gi). (Giii) As in (Gii) except the samples were purified according to the scheme. The purified samples were then analyzed by anti-SRC-3 to ensure that the detected bands are indeed ubiquitinated SRC-3. Figure S4A ); an SRC-3 mutant that did not interact with ER (SRC-3 AAA) was devoid of estradiol-induced enhancement ( Figure 7Ai , top panel, lanes 3 and 4). We also found that this enhanced ubiquitination was selective for ER, AR, and their respective ligands since PR and progesterone had no detectable effect on SRC-3 ubiquitination (Figure 7Ai and Figure S4B ). Concomitant with increased ubiquitination, increased S505 phosphorylation was detected on the wild-type but not on the mutant SRC-3 (Figure 7Ai , second panel from top). Importantly, estradiol-enhanced ubiquitination of SRC-3 also was observed on endogenous SRC-3 prepared from MCF-7 cells (Figure 7Aii) , and it was mediated by Fbw7a and GSK3 since knockdown of Fbw7a or GSK3 abolished the estradiol-mediated induction of SRC-3 ubiquitination (Figure 7Aiii and iv, respectively; compare to Figure 7Aii , top panel). Concomitant with the reduction of SRC-3 ubiquitination, we also found that knockdown of Fbw7a or GSK3 greatly reduced the estradiol-induced cellular interactions between SRC-3 and ER (Co-IP) (Figure 7Aii , bottom panel, 3.7-fold versus iii and iv, bottom left panels, 1.3-and 1.8-fold, respectively).
To demonstrate that the intrinsic transcriptional activity of SRC-3 is affected by GSK3 and Fbw7a, we first showed that only the wild-type GSK3, not the kinase-defective mutant, enhanced the intrinsic transcriptional activity of GAL4-SRC-3 in an S505 phosphorylation-dependent manner (Figure 7Bi , compare columns 4-6 and 1-3). Furthermore, only the wild-type Fbw7a, not the F box-deleted mutant, enhances the activity of GAL4-SRC-3 in a dosage-dependent manner ( Figure 7Bii ). As expected, GSK3 and Fbw7a synergistically enhanced the activity of SRC-3 (Figure 7Biii ), and mutation of phosphorylation sites (S505, S505/509) and ubiquitination sites (K723 and K786 but not K1194) abolished the enhancement of SRC-3 activity induced by Fbw7a ( Figure S5 ). The results suggest that phosphorylation-dependent ubiquitination of SRC-3 confers a transcription activation function prior to promoting SRC-3 degradation.
Because Fbw7a, similar to estradiol, increased not only the multi-(mono)ubiquitination but also the polyubiquitination of SRC-3 ( Figures 4E and 7A) , we transfected the wildtype ubiquitin molecule or a ubiquitin mutant with all seven lysines mutated to arginines (UbKO) to distinguish the functions of multi-(mono)ubiquitinated SRC-3 from that of polyubiquitinated SRC-3. In this scenario, the wildtype ubiquitin supports both multi-(mono)ubiquitination and polyubiquitination of SRC-3, whereas UbKO supports only multi-(mono)ubiquitination of SRC-3. Our results showed that Fbw7a enhanced GAL4-SRC-3 activity in the presence of wild-type ubiquitin as well as UbKO in a dosage-dependent fashion (Figure 7Biv , compare columns 4-6, 7-9, and 10-12). Interestingly, SRC-3 appears even more active in the presence UbKO than in the presence of wild-type ubiquitin. Our results suggest that multi-(mono)ubiquitination of SRC-3 is sufficient for achieving its full potential as a coactivator. Because both multi-(mono)ubiquitination and polyubiquitination occur on SRC-3 under normal physiological conditions, we suggest the possibility that transition from multi-(mono)ubiquitination (activation) to polyubiquitination (degradation) couples with transcriptional activation to control the amplitude and lifetime of SRC-3 coactivator activity.
To substantiate that transition from multi-(mono)ubiquitination to polyubiquitination of SRC-3 is coupled with the transcriptional coactivation of ER, we determined the ubiquitinated forms of SRC-3 in the presence or absence of transcription. Both multi-(mono)ubiquitination and polyubiqitination of SRC-3 were enhanced in the presence of estradiol ( Figure 7C, lanes 1 and 2) . In marked contrast, when active transcription was blocked by actinomycin D, estradiol induced only the multi-(mono)ubiquitinated form of SRC-3 ( Figure 7C, lane 3) . Notably, the protein interactions between SRC-3 and ER induced by estradiol were not affected by actinomycin D ( Figure 7C , third and fourth panels, lanes 1 and 3) . In addition, we demonstrated a more rapid turnover of SRC-3 when it is involved in transcriptional activation (particularly during the first 2 hr after addition of estradiol, Figure 7D , compare lanes 1 [100%], 2 [75%], and 6 [40%]); this rapid turnover of SRC-3 was retarded when transcription was prevented by actinomycin D ( Figure 7D, lanes 2 [75%] , 6 [40%], and 10 [67%]), suggesting that the transition from multi-(mono)ubiquitination to polyubiquitination of SRC-3 is indeed coupled with transcriptional progression. We next tested the ubiquitination of an SRC-3 mutant that is transcriptionally inactive due to deletion of the region responsible for interaction with CBP/p300. Unlike the wild-type SRC-3, neither phosphorylation of S505 nor ubiquitination of this inactive SRC-3 (delCID) can be induced by estradiol (Figure 7Ei , top two reporter gene, expression plasmids for AR, wild-type or SRC-3 mutants, and with or without Fbw7a as indicated. Results were from three independent experiments performed in duplicate. The error bars represent standard error of the mean. (E) HeLa cells grown in phenol red-free medium (supplemented with 5% charcoal-stripped FBS) were transfected with ER and the indicated SRC-3 constructs. Estradiol (10 À8 M) was added to the transfected cells 18 hr posttransfection as indicated and incubated for an additional 24 hr. The total RNAs were prepared as described and used for RT-PCR to detect the induction of an endogenous ER target gene pS2. The levels of ER, Flag-SRC-3, and GAPDH from the same samples were detected with specific primers and used as a loading control. Results of a representative from two independent experiments with similar results were shown. panels, compare lanes 2 and 4). In contrast to the wildtype SRC-3 ( Figure 7D ), the half-life of this mutant is not altered in the presence of estradiol (Figure 7Eii ). To provide additional substantiation that multi-(mono)-ubiquitinated SRC-3 is sufficient for its initial intracellular recruitment by ER, we performed Co-IP experiments from cells exposed to either wild-type ubiquitin or UbKO. The coimmunoprecipitated SRC-3 was then run on SDS-PAGE optimized for the separation of SRC-3 with different mobilities. The slower-migrating SRC-3 is enriched in both the presence of wild-type ubiquitin or UbKO ( Figure 7F , compare lanes 2, 4, and 5), indicating again that the multi-(mono)ubiquitinated SRC-3 is sufficient for interaction with ER.
Since SRC-3 is essential for recruitment of RNA Pol II and transcriptional activation of ER target genes (Shao et al., 2004) , we performed crosslinking experiments to determine Pol II recruitment and to firmly demonstrate that multi-(mono)ubiquitinated SRC-3 is sufficient to support transcriptional activation by ER (Schmitt-Ulms et al., 2001) . To ensure that SRC-3 is exclusively multi-(mono)-ubiquitinated, UbKO was used. As expected, multi-(mono)ubiquitination of SRC-3 is enhanced by estradiol in the presence of UbKO (Figure 7Gi ). Next, we crosslinked cells with formaldehyde following treatment with estradiol and then protein extracts were subjected to two rounds of immunoprecipitation (IP). The crosslinked immunoprecipitates from the first round IP with ER antibodies were crosslink-reversed and used for reimmunoprecipitation with Pol II antibodies followed by western blotting to detect phosphorylation on Pol II CTD. Our results showed that multi-(mono)ubiquitinated SRC-3 is able to recruit Pol II phosphorylated at both Ser5 and Ser2 of the CTD (Figure 7Gii ). Since phosphorylation of Ser5 occurs during transcription initiation and phosphorylation of Ser2 is enriched toward the 3 0 end of the gene during transcription, our results indicate that multi-(mono)ubiquitinated SRC-3 is capable of recruiting active transcription machinery.
Finally, to directly prove that multi-(mono)ubiquitinated SRC-3 is active in transcription, we compared the activities of precise quantities of purified multi-(mono)ubiquitinated and nonubiquitinated SRC-3 (Figure 7Hi and legend for details) in a chromatin-based in vitro transcription
The immunoprecipitated SRC-3 and the coimmunoprecipitated ER levels were detected by anti-SRC-3 and anti-ER, respectively. The numbers indicated the relative intensity of coimmunoprecipitated ER in the presence or absence of estradiol. The ligand-independent interaction was set as 1. (Gi) Protein extracts from HEK293 cells transfected with ER, SRC-3, and HA-UbKO were used to determine the effects of estradiol (10 À8 M, 1 hr) on SRC-3 ubiquitination. Ubiquitination of SRC-3 was determined as described previously. (Gii) As in (Gi), except the cells were crosslinked with formaldehyde (1%) prior to preparation of protein extracts. Immunoprecipitation was first carried out with ER antibodies, and the immunoprecipitates were subject to crosslink reversal and then used for second immunoprecipitations with Pol II antibodies. The pellets and the supernatant from the second immunoprecipitation were immunoblotted with the indicated antibodies. The numbers indicated the relative intensity of coimmunoprecipitated Pol II phosphorylated at the indicated amino acids of CTD in the presence or absence of estradiol. The value in the absence of estradiol was set as 1.
(Hi) The multi-(mono)ubiquitinated SRC-3 was purified from HEK293 cells cotransfected with Flag-SRC-3 and HA-UbKO, and the nonubiquitinated SRC-3 was purified from cells transfected with Flag-SRC-3. Similar amounts of purified multi-(mono)ubiquitinated and nonubiquitinated SRC-3 were shown. (Hii) Chromatin-based in vitro transcription assay was performed as previously described . The error bars represent standard error of the mean. assay. Our results showed that multi-(mono)ubiquitinated SRC-3 is transcriptionally more active with ER than its nonubiquitinated counterpart (Figure 7Hii ). Since estradiol and Fbw7a enhanced the ubiquitination of SRC-3 ( Figures  4D and 7C ) but not ER ( Figure 7I ), our combined results indicate that multi-(mono)ubiquitination promotes SRC-3 binding to ER and enhances its transcriptional function; continued transcriptional activity then promotes the transition from multi-(mono)ubiquitination to polyubiquitination and eventual degradation of SRC-3.
DISCUSSION
In this report, we identified GSK3 as a kinase that phosphorylates SRC-3 on S505 and demonstrated that this phosphorylation modulates SRC-3 transcriptional function and turnover. SRC-3 contains a motif (phosphodegron) in the S505-S509 region ( Figure 3C ), which targets SRC-3 for degradation by the ubiquitin-dependent proteasome pathway in a manner that is dependent on phosphorylation of S505 and S509 (Figure 4Cii ). Signaling through the Akt/PKB-GSK3 pathway affected SRC-3 by phosphorylation of S505. Knockdown of GSK3 extended the half-life of SRC-3 and resulted in elevated endogenous SRC-3 levels in MCF-7 cells ( Figure 3A) . Overexpression of wild-type GSK3 but not kinase-defective GSK3 (KD) promoted ubiquitination of SRC-3 ( Figure 3D ), indicating that both the kinase activity of GSK3 and phosphorylation of S505 in SRC-3 are required.
SCF Fbw7a Is an SRC-3-Selective E3 Ligase
We identified SCF Fbw7a as an E3 ligase that binds to SRC-3 in an S505 phosphorylation-dependent manner ( Figure 4Ci ) and that is responsible for the further ubiquitination of SRC-3 ( Figure 4A ). To substantiate the role of SCF
Fbw7a
, we showed that knockdown of SCF Fbw7a increased SRC-3 cellular levels ( Figure 4Bi ) and overexpression of Fbw7a significantly reduced the half-life of SRC-3 (Figure 4Bii ). Furthermore, only the wild-type, not the mutant Fbw7a containing a deletion of the critical F box sequence (Fbw7adelF), promoted ubiquitination (Figure 4F ) and activation of SRC-3 (Figure 7Bii ). Interestingly, SCF Fbw7a selectively enhanced ubiquitination of SRC-3 and not that of the homologous SRC-1 and SRC-2 family members ( Figure 4G ). Sequence analysis revealed that neither SRC-1 nor SRC-2 contains the specific degron/actron consensus element ( 505 SPMAS 509 ) that we identified within SRC-3.
Discovery of a Proteolysis-Independent Role for SRC-3 Ubiquitination in Its Coactivational Function
One of the most interesting aspects of this study is the discovery of an unexpected enhanced transcriptional coactivation function for SRC-3 that is determined by (mono)-ubiquitination of SRC-3 within its receptor interaction domain (RID) ( Figure 5B ) at K723 and K786 ( Figures 5C-5E ). Fbw7a directly ubiquitinates SRC-3 at K723 and K786 in an S505 phosphorylation-dependent manner ( Figure 5E ). These two ubiquitination sites are located in close proximity to the LXXLL motifs responsible for the binding to nuclear receptors, and mutation of SRC-3 K723 and K786 to arginines dramatically reduced the ligand-induced interaction with estrogen receptor (ER) ( Figure 6B ). Concomitantly, phosphorylation of S118 on ER, a critical site-specific hallmark for ER activation, was diminished in K723R or K786R as compared to K1194R or wild-type SRC-3. The importance of ubiquitination of SRC-3 for its coactivation activity is supported by the ability of Fbw7a to further enhance the ability of the wild-type SRC-3 but not the K723R or K786R SRC-3 mutants to coactivate ER-regulated reporter and endogenous genes ( Figure 6E ). Knockdown of GSK3 and Fbw7a abolished the ubiquitination of SRC-3 and abolished the interaction between ER and SRC-3 and the induction of several ER target genes by estradiol ( Figures 7A and 6F) . Accordingly, we demonstrated that Fbw7a was recruited to the promoter regions of ER target genes along with SRC-3 and ER in an estradiol-dependent fashion; knockdown of Fbw7 significantly reduced recruitment of SRC-3 and ER (Figure 6G) . Our results substantiate that S505 phosphorylation-dependent ubiquitination of SRC-3 on K723 and K786 by Fbw7a is critical for SRC-3 coactivation of ERdependent genes and that this region also acts as an ''actron.'' A Phosphorylation-Dependent Ubiquitination Code Regulates SRC-3 Transcriptional Function and Transcription-Factor Specificity Since SRC-3 can function as a coactivator for a variety of transcription factors, regulation of activity and specificity toward different transcription factors is an issue of critical importance. Phosphorylation-dependent ubiquitination, in addition to modulating cellular SRC-3 turnover, regulates SRC-3 coactivational activity and transcription factor specificity. In context with ER, estradiol induces rapid phosphorylation of SRC-3 and assembly into a complex containing other coactivators with enhanced potential for transcriptional activation . Our present results indicate that a coordinated estradiol-mediated increase in site-specific phosphorylation leads to multi-(mono)ubiquitination and activation of SRC-3 ( Figures  7A, 7E , and 7H), followed by enhanced SRC-3 binding to ER, ER phosphorylation ( Figure 6B ), and efficient estradiol-mediated gene expression ( Figure 6F ).
A Ubiquitin Clock Regulates the Transcriptional Lifetime of SRC-3
When the multi-(mono)ubiquitinated chain is extended on SRC-3 during the course of transcription, it is generally accepted that the molecule will be degraded by the proteasome when the polyubiquitin chain reaches $4-5+ additions of ubiquitin (Varshavsky, 2005) . This interpretation is substantiated by the following observations: (1) the processivity of multi-(mono)Ub SRC-3 to poly-Ub SRC-3 is inhibited by interrupting transcription with actinomycin D ( Figure 7C) ; (2) in contrast to the wild-type SRC-3, the S505 phosphorylation-dependent ubiquitination and estradiolinduced degradation are lost on a transcriptionally inactive SRC-3 mutant (delCID) ( Figures 7D and 7E) ; and (3) monoubiquitinated SRC-3 is transcriptionally more active than its nonubiquitinated counterpart in a direct chromatinbased transcription assay ( Figure 7H ). By this scenario, multi-(mono)ubiquitination plays both a transcriptional activation role and also initiates a process that ultimately results in turnover of SRC-3 when it reaches a time-dependent later stage of polyubiquitination in the presence of estradiol. In this way, the ubiquitination region of SRC-3 acts as both an ''actron'' and a ''degron.'' Since ubiquitination depends on the prior phosphorylation of SRC-3, our results confirm the importance of an inherent SRC-3 phosphorylation code and now include ubiquitination of SRC-3 as a critical element of this transcriptional code (Wu et al., 2002 .
It was reported previously that proteasomal degradation of ER and coactivators is required for continuous efficient transactivation by ER (Lonard et al., 2000) . Our current results suggest that ubiquitination of SRC-3 is a biphasic event and that transition from multi-(mono)ubiquitination to eventual polyubiquitination is coupled to transcriptional progression in the presence of ER (and AR). Since multi-(mono)ubiquitination of SRC-3 is sufficient for its initial recruitment by ER ( Figure 7C ) and for RNA Pol II recruitment ( Figure 7G ), as well as for the subsequent polyubiquitination and degradation of SRC-3 ( Figures 7D and 7E) , an increased local concentration or activity of Fbw7a by recruitment onto promoters by SRC-3 ( Figure 6G ) could both promote transcription and allow clearance of the promoter in preparation for subsequent rounds of nascent cofactor recruitment and transcriptional initiation. Our results indicate that in response to select physiologic stimuli, phosphorylation-dependent ubiquitination regulates both the function and relative transcriptional specificity of SRC-3. This posttranslational code of modifications serves as a ''transcriptional time clock'' that determines the functional lifetime of the coactivator.
